tradingkey.logo

ADMA Biologics Inc

ADMA
查看詳細走勢圖
16.430USD
+0.490+3.07%
收盤 02/06, 16:00美東報價延遲15分鐘
3.92B總市值
18.51本益比TTM

ADMA Biologics Inc

16.430
+0.490+3.07%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+3.07%

5天

-5.03%

1月

-12.70%

6月

-1.91%

今年開始到現在

-9.92%

1年

-1.68%

查看詳細走勢圖

TradingKey ADMA Biologics Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

ADMA Biologics Inc當前公司基本面數據相對非常健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在藥品行業排名32/159位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為25.67。中期看,股價處於上升通道。近一個月,市場表現較差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

ADMA Biologics Inc評分

相關信息

行業排名
32 / 159
全市場排名
95 / 4521
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
極度看好

ADMA Biologics Inc亮點

亮點風險
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
業績高增長
公司營業收入穩步增長,連續3年增長176.77%
業績轉盈
公司業績轉盈,最新年度盈利美元
估值合理
公司最新PE估值18.51,處於3年歷史合理位
機構加倉
最新機構持股228.97M股,環比增加0.04%
CI 精選加拿大股票基金持倉
明星投資者CI 精選加拿大股票基金持倉,最新持倉3.19K股

分析師目標

基於 3 分析師
買入
評級
25.667
目標均價
+55.65%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

ADMA Biologics Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

ADMA Biologics Inc簡介

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
公司代碼ADMA
公司ADMA Biologics Inc
CEOGrossman (Adam S)
網址https://www.admabiologics.com/
KeyAI